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Much research on transcription factor biology and their genetic pathways has been undertaken over the last
30 years, especially in the field of developmental biology and cancer. Yet, very little is known about the molecular
modalities of highly dynamic interactions between transcription factors, genomic DNA, and protein partners.
Methodological breakthroughs such as RNA-seq (RNA-sequencing), ChIP-seq (chromatin immunoprecipitation
sequencing), RIME (rapid immunoprecipitation mass spectrometry of endogenous proteins), and single-molecule
imaging will dramatically accelerate the discovery rate of their molecular mode of action in the next few years.
From a pharmacological viewpoint, conventional methods used to target transcription factor activity with
molecules mimicking endogenous ligands fail to achieve high specificity and are limited by a lack of identification
of new molecular targets. Protein-protein interactions are likely to represent one of the next major classes of
therapeutic targets. Transcription factors, known to act mostly via protein-protein interaction, may well be at
the forefront of this type of drug development. One hurdle in this field remains the difficulty to collate structural
data into meaningful information for rational drug design. Another hurdle is the lack of chemical libraries meeting the
structural requirements of protein-protein interaction disruption.
As more attempts at modulating transcription factor activity are undertaken, valuable knowledge will be accumulated
on the modality of action required to modulate transcription and how these findings can be applied to developing
transcription factor drugs. Key discoveries will spawn into new therapeutic approaches not only as anticancer targets
but also for other indications, such as those with an inflammatory component including neurodegenerative disorders,
diabetes, and chronic liver and kidney diseases.
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The concept of pharmacological manipulation of protein-
protein interaction (PPI) was clearly demonstrated with
taxane anticancer drugs, paclitaxel and docetaxel,
identified half a century ago. These compounds of
natural and semisynthetic origins block microtubule
depolymerization and mitosis in tumor cells via a
mechanism of stabilization of tubulin heterodimers,
eventually leading to apoptosis [1]. In 2014, the mar-
ket for taxane anticancer drugs was valued at around
US$6 billion for United States, Japan, and Europe [2].* Correspondence: m.francois@imb.uq.edu.au
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unless otherwise stated.It is now widely admitted that a large majority of the
estimated 3,000 druggable proteins [3] function as com-
plexes within a network of interactions [4-6], rather than
acting as single effectors. As a result, the modulation of
protein-protein interactions by small organic molecules, so-
called “protein-protein interaction disruptors” or PPIDs, of-
fers innovative therapeutic avenues [7,8].
Within the field of PPIDs’ discovery, particular types
of protein-protein interactions are easier to target than
others, such as transmembrane, cytoskeleton, and mi-
totic proteins, as well as nuclear receptors, with exciting
anticancer and anti-infective indications. Nuclear proteins
such as transcription factors (TFs) still remain a challenge
to manipulate using chemical-based strategies. Pharmaco-
logical management of transcription factors is usuallyal. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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upstream phosphokinase (lack of specificity) [9,10] or
via mimicking endogenous ligands (nuclear receptors)
[11,12]. Despite major hurdles in specifically targeting
transcription factor activity, their central role in control-
ling cell signaling and their mode of action as dynamic
complexes position them at the forefront as targets of
choice for PPIDs (Figure 1).Figure 1 Advantages of targeting transcription factor protein-prote
cell-signaling nodes (e.g., kinase) lacks specificity because of the interco
Targeting transcription factors, downstream effectors of cell signaling, a
is likely to be a more specific approach [13].In this review, we aim to reposition the study of
transcription factor biology in its historical context
and from there to weigh the impact of recent meth-
odological and conceptual breakthroughs on future
developments. We will briefly discuss strategies to de-
velop pharmacological manipulation of transcription
factors, focusing on protein-protein interactions and
small compounds.in interactions over conventional targets. Targeting upstream
nnected nature of cell signaling and its numerous feedback loops.
ble to control specific gene groups via specific protein associations,
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Basic principles of eukaryotic transcription
Eukaryotic transcription is a complex mechanism clas-
sically requiring core promoter factors and gene-specific
transcription factors, which assemble cooperatively on
cognate DNA elements located on the promoter, up-
stream of the gene coding region, marked by the ATG
“start” codon [14]. Core promoter factors and RNA poly-
merase II assemble on the gene promoter at the tran-
scription start site, consisting in a broad CpG island or a
TATA box [14,15]. Gene-specific transcription factors,
conversely to core promoter factors, display specificity
towards sets of target genes [16,17]. They bind to DNA
elements that may be within the proximal promoter
(<5 kb) or in the remote part of the chromatin thou-
sands of nucleotides away. Co-regulator proteins in turn
help connect DNA-binding TFs to the general transcrip-
tional machinery or locally modify chromatin structures
to facilitate transcriptional activation [18,19]. RNA poly-
merase II is then recruited via the mediator, a large
protein complex required for almost all transcriptions
of RNA polymerase II promoters, finally initiating gene
transcription [20].
Two other groups of transcription factors, not directly
involved in the final steps of transcription initiation, yet
pivotal in transcriptional regulation, should be men-
tioned. These are pioneer transcription factors that can bind
directly to condensed DNA and “chromatin-associated”
high-mobility group (HMG) proteins, very close to pion-
eer transcription factors, which bind to DNA with low se-
quence specificity, except for the Sox sub-family [21,22].
Pioneer transcription factors (for example, CTCF, GATA)
and HMG proteins (for example, HMGA, HMGB) modu-
late chromatin architecture and are more abundant in
cell nuclei compared with “gene-specific” transcription
factors [21,23-25]. Pioneer transcription factors and
HMGA and HMGB proteins are able to open up histone-
occluded chromatin, higher-order chromatin structures,
or repressor complexes [21,23]. The Sox sub-family of
HMG proteins, on the other hand, is not considered
able to do so, according to a new functional classifi-
cation based on transcription factors’ effect on chro-
matin architecture [26,27]. In this new classification,
based on computational analysis of DNase I-digested
genome sequence, the Sox sub-family of HMG proteins
is positioned in an intermediate group between pioneer
and gene-specific transcription factors, the “migrant” tran-
scription factors, unable to open condensed chromatin
[26,27]. Both pioneer transcription factors and HMG
proteins—including Sox—control the timing of tran-
scription during development and cell differentiation
and are therefore key factors in global transcriptional
regulation [21,23,28].Direct chemical modulation of TFs’ activity is an expand-
ing field, as already demonstrated with nuclear receptors,
exploiting their ability to capture small endogenous li-
gands, in structurally well-defined binding sites [29]. In
hormone-dependent cancers, like breast and prostate
cancers, drug resistance to nuclear receptor antagonists
is a frequent problem that may be avoided by targeting
accompanying pioneer factors [30,31]. Not only for this
reason but also because of their key role in early develop-
ment and cancer, pioneer transcription factors as well as
HMG proteins are the next two groups likely to open new
therapeutic windows [21,32].
TF functions: current state of knowledge
The first transcription factor ever discovered was the sim-
ian viral repressor SV40 T antigen (simian virus rumor
antigen) in the late 1970s [33]. In the early 1980s, the first
human transcription factor was discovered, the potent ac-
tivator zinc finger transcription factor Sp1 [34]. Twenty
years later, by the time the human genome sequence was
published, JC Venter and collaborators predicted the total
number of transcription factors to be 1,500, making it the
second most common molecular function for a gene pro-
tein product after enzymes [35]. However, of this pre-
dicted 1,500 protein-strong transcription factor proteome,
less than 5% were purified and characterized by 2001 [36].
Projects of automated annotation of genomic functional
elements, like the ENCODE consortium initiated in 2003
(histone marks, transcription factor binding, chroma-
tin regulators, RNA-binding proteins, etc.), FANTOM5
(regulatory elements such as enhancers), or, in 2010, the
smaller Dragon database (transcription co-regulators and
transcription factor-interacting proteins, TcoF-DB), have
started to identify, locate, and sequence functional ele-
ments [37-39]. These ventures have not only revolution-
ized our understanding of genome structure and function
but have also given us the false notion that we have gained
knowledge in the biochemical properties of TFs. Since
2001, the predicted number of human TFs has been re-
fined to about 1,700–1,900, and less than 200 co-
regulators. However, only a meager 62 TFs have been
functionally validated, not just annotated according to
their DNA-binding coordinates [13,38]. Expanded ex-
perimental opportunities to perform quantitative study
of TF biochemical properties, as measured with either
cell-free (requiring recombinantly expressed/purified TF)
or reporter-based technologies, are only available for a
restricted number of TFs [13,40]. Without this level
of experimental “tractability”, further studies required
for target validation are impossible.
The discipline of developmental biology has contrib-
uted the most to the identification and characterization
of TFs, prevalently in non-human organisms, with obser-
vations not necessarily applying to human orthologues
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transcription factors (consisting of a DNA-binding do-
main and a transactivation domain) directly responsible
for diseases or syndromes, the largest portion involves
developmental defects [13,41-43]. The second and third
fields of investigation that have contributed the most to
transcription factor discovery are the study of cell sig-
naling and cell metabolism [13]: cell signaling because
the study of interconnected signaling pathways always
converges at transcription factors [17] and cell metab-
olism because metabolic processes are instructed by
nuclear receptors, capable of directly activating gene
transcription upon binding of endogenous hormone
ligands [44]. In summary, the sheer number of studies
published on human transcription factors, over 90,000
in 30 years (for the top 20 transcription factors), and the
rapid development, in the last decade, of electronic anno-
tations generated by sequence search algorithms, together
conceal the fact that we have very limited knowledge on
how human TFs function [40].
TF proteome: recent landmark advances in profiling
methods
DNA microarray and qPCR analyses have confirmed
that transcription factors are consistently expressed at
lower levels than other genes across 32 human tissues
[45]. This seems logical as a single transcription factor
can trigger the generation of many copies of mRNA
from a single target gene. In the nuclear compartment,
however, there is seldom but direct evidence that the
local concentration of TFs can vary at least several fold.
HMG proteins, HMGA2 and HMGB2 for instance, are
three to six times more abundant than other TFs in hu-
man epithelial cell line nuclear extract [24]. Sox2, an-
other HMG protein, reaches almost millimolar levels in
the nucleus of embryonic stem cells [25]. From a law of
mass action perspective, keeping gene-specific transcrip-
tion factor abundance low, i.e., spanning the Kd values
of the best binding sites, could prevent them from bind-
ing to lower affinity sites, with an undesired transcrip-
tional effect [46]. Similar observations were made in
bacteria [47]. Conversely, for TFs at the top of the hier-
archy, like pioneer TFs that control multiple distant gen-
omic areas, a higher nuclear concentration is required
for rapid 3D diffusion [25,47]. At the whole-tissue level,
the low abundance of TFs, along with nucleus compart-
menting, and the difficulty to separate DNA-binding
proteins from genomic DNA explain why transcription
factor affinity purification and pull-downs have been
technically challenging [36,48,49]. In 2007, however, with
the generalized usage of the genome-wide protein binding
assay “ChIP-seq” (chromatin immunoprecipitation se-
quencing) later on combined with protein mass spectrom-
etry (“rapid immunoprecipitation mass spectrometry ofendogenous proteins”, RIME), functional study of tran-
scription factors dramatically accelerated [50]. Further, a
new remarkable approach has been developed that in-
volves transcription factor affinity purification with a
DNA concatemer composed of multiple tandem repeats
of a specific responsive element. The method developed
over 20 years ago was not initially able to improve on
standard affinity chromatography methods [36,51]. In a
recent development, a DNA concatemer made of the tan-
dem juxtaposition of 100 selected transcription factor-
responsive elements allowed authors to identify, and
purify, almost 900 transcription factors from the nu-
clear extract of 11 different mammalian cell lines, as well
as measure their DNA binding activity in one single puri-
fication step [24]. This new methodology in association
with new-generation rapid MS-based protein identifi-
cation brings transcription factor proteomics to the
throughput level of RNA-seq (RNA-sequencing) [24].
DNA concatemer pull-down analysis is now able to
measure proteome-wide changes in transcription factor
binding activity in response to drug treatment in any cell
line or tissue. These recent methodological breakthroughs,
along with single-molecule imaging of hundreds of milli-
second span-lived nucleus enhanceosomes (transcription
factor assembly on their cognate DNA target sites), will
shed light onto molecular mechanisms of transcriptional
regulation [24,25]. As a consequence, refined classification
of transcription factors based on nuclear stoichiometric
abundance, association-dissociation kinetics, co-regulating
partners, and the type of DNA they are bound to (methyl-
ated, condensed) will emerge and will challenge the exist-
ing classification [52,53]. These recent breakthroughs
undoubtedly lift major impediments for key players in
drug development, in the study of transcription factors as
potential molecular targets.
Transcription factors as molecular targets
Basic concepts of target protein “druggability”
Over the last two decades, drug discovery research has
been transitioning from searching for compounds active
against diseases but with unknown targets to screening
for specific inhibitors of disease-relevant proteins [54].
The basic concept of target druggability was coined in
2002 by Hopkins and Groom and mostly remains an
empirical issue, constantly reassessed with each new at-
tempt to find drugs [3].
All drugs currently available on the market target less
than 500 proteins, of both pathogen and human host ori-
gins. More than 50% of these drugs target three types of
proteins only, class I G protein-coupled receptors (GPCR;
27%), nuclear receptors (13%), and ion channels (13%)
[55,56]. Advantageous physicochemical properties for
drug binding can be estimated for any disease-relevant
protein: simply put, the presence of a deep hydrophobic
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ing of a drug-like molecule, in turn, able to modulate
the target’s “activity” [57]. To some extent, off-target ad-
verse effects can also be predicted based on the same binding
site characteristics, as well as knowledge accumulated from
decades of clinical trials and emerging inter-disciplinary
systems biology [58]. Other, less tangible aspects of drugg-
ability are much harder to predict, including any “ex-
perimental hurdles” and unforeseen adverse effects,
until trialed [57].
TF “druggability” and PPIs
General problem of targeting protein-protein interactions
Application of basic concepts of target “druggability” to
TFs highlights a number of important challenges. Modu-
lation of TF activity can be achieved via a few different
approaches, including direct or indirect modulation of
their own expression, modulation of their DNA binding
activity, and modulation of their ability to interact with
partner proteins (Table 1). We will focus this discussion
on protein-protein interface inhibition by small com-
pound antagonists. Boundaries between small compounds,
peptides, and peptide mimetics are blurred; small com-
pound PPI disruptors (PPIDs) are heavier, more hydro-
phobic, more rigid, and more planar than conventional
small compound drugs, and peptide motifs are often in-
cluded in their structure as part of their rational design
[59,60]. Most transcription factors form homo- or hetero-
dimers to be part of a larger complex subunit that oper-
ates in a cooperative fashion (Figure 2). Whether DNA
binding affinity and specificity for cognate DNA gain from
TF PPI [61,62] or not [63] remains a controversial ques-
tion. Even so, disturbing the dimerization/partner recruit-
ment of a crucial TF to exert influence on gene expression
is already a proven effective strategy for nuclear receptors
with a protein interface centered around a well-defined
binding pocket [11,12,16]. For other transcription factors,
targeting protein-protein interactions with 10-Å-longTable 1 Summary of direct TF inhibition strategies
Mode of
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pro-inflammatosmall molecules is a challenging task owing to the large,
diffuse, and polished surface areas involved in protein-
protein binding (1,500–3,000 Å2 compared to a few hun-
dreds to a thousand for a “classic” binding pocket) and the
lack of obvious concave binding pockets at many protein-
protein interfaces or allosteric sites [64]. In addition, high-
throughput screening technologies to identify compounds
able to disrupt protein-protein interfaces are not routinely
available for various reasons [65]. The main limitation of
in vitro homogenous protein-protein interaction assays is
access to sufficient amounts of the functional proteins
themselves. Even so, post-translational modifications fun-
damental for protein functionality can be lacking in recom-
binant proteins. Finally, purification of TFs is notoriously
difficult, as they tend to bind to genomic DNA. Despite
these technological limitations, a eukaryotic cell-free pro-
tein expression system coupled to AlphaScreen-based
measurement of protein-protein interaction has been
described, enabling rapid mapping of protein interaction
networks and high-throughput screening for protein-
protein interaction inhibitors [66]. This study has opened
the way to target TFs as part of a network of interactions
rather than addressing individual PPIs specific to a few
particular TFs.
Although protein-protein interfaces are large, studies
show that amino acids usually found at the center of the
interface and representing less than half of its surface
contribute to most of the binding energy [77]. In the
past 5 years, there has been remarkable progress in iden-
tifying small molecules that bind to these interfaces.
Empirical experience shows however that compounds
binding to the aforementioned “core” amino acids alone
are not high-affinity inhibitors and need additional
sources of affinity, like pockets not naturally engaged by
protein partner(s) [64].
A protein involved in protein-protein interactions often
uses the same interface to bind “promiscuously” to several
protein partners [78]. In turn, one can easily predict that abacks Examples/indication
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responsive element
+
Inhibitor binds to DNA-binding
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Inhibitor binds to a prot-prot interaction
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Figure 2 Mode of action of transcriptional activation inhibitors. Small compounds directly inhibiting transcriptional activation can act by
targeting DNA (blue), or transcription factors/co-activators, either preventing DNA binding (red and green) or altering protein conformation or
protein-protein interaction (yellow). Inspired from [16].
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will also show some promiscuity for partner proteins
interacting with the target protein initially selected for its
design. Pharmacological promiscuity is considered to be a
bad omen in classical drug discovery projects, focused for
example on enzymes or G protein-coupled receptors (the
“one drug-one target” paradigm), leading to adverse drug re-
actions and obscuring pharmacodynamics effects in animal
models. If protein-protein interactions are to be “drugged”
in the near future, the aforementioned “promiscuity” con-
cept will have to be redefined in a more restrictive manner
for small molecules that disrupt these interfaces. Here, the
concept of selectivity requires a paradigm shift. For a PPID
to be functional, the small-molecule inhibitor will have to
“excise” its target protein “out” of an interaction network,
meaning that some promiscuity towards surrounding part-
ner proteins may in fact be beneficial. This will prevent re-
dundancy mechanisms that are often in place to make up
for the loss of activity of a specific transcription factor.
Risks associated with targeting TFs, the “focal point” of cell
signaling pathways
“Drugging” transcription factors, the “point of convergence”
of multiple signaling pathways, in turn controlling mul-
tiple target genes, is largely considered a perilous task, due
to the broad consequences of modulating their activity.
Human genome analysis has recently revealed that cell
signaling networks consist of approximately 3,000 genes,
1,800 involved in intra-cellular signaling (kinases andphosphatases implicated in protein phosphorylation) and
1,300 in cell-cell communication [79]. In comparison to
the 1,700 to 1,900 human transcription factor proteome,
this amounts to an average “ratio” of approximately 3,000/
1,900 ≈ 1.6 “signaling” genes per transcription factor. This
ratio, not as “high” as suspected, is likely to leave
room to redundancy mechanisms for most TFs [13]. Simi-
lar concerns were raised 20 years ago about protein ki-
nases “serving critical cellular functions” and “difficult to
target specifically”, when the first-generation tyrosine kin-
ase inhibitor “Gleevec” was discovered and fast-tracked to
market 10 years later [80]. Today, 10% of experimental
and marketed drugs are targeting serine/threonine and
tyrosine protein kinases, generating a US$20.2 billion mar-
ket in 2014 [3].
Very recently, in a lymphoblastoid cell line, the expres-
sion of 59 transcription factors and chromatin modifiers
was independently knocked down (by at least 50%, using
small interfering RNAs) and down-regulated genes were
identified in three independent microarray experiments
[81]. The number of genes differentially expressed approxi-
mately ranged from 40 to 4,000, depending on the knock
down experiment. Microarray data were compared to data
obtained with negative control siRNA, and the reduced
list was then cross-checked with ChIP-seq and DNase-seq
binding maps of the aforementioned transcription factors
and chromatin modifiers [82]. Binding of a knocked-down
transcription factor was deemed functional only if a
binding site was within 10 kb of the transcription start site
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tially expressed genes could be associated with any decrease
of TF binding, and the median level of down-regulation
for these target genes was less than 10% compared to
negative control. This work illustrates our current lack of
understanding of TF redundancy mechanisms and defines
the need to develop proper “biochemical” functional as-
says in vitro and in vivo.
Modes of intervention
Targeted indications
Cancer It is widely accepted that most anticancer chemo-
therapies are marred with taxing side effects and risks of
relapse with resistant tumors. Archaic DNA-alkylating
cisplatin, for instance, the first member of platinum-
containing anticancer drugs approved by FDA more
than 35 years ago, displays acute and indiscriminate cyto-
toxicity, not to mention common relapse with cisplatin-
resistant tumors. Yet, it is still, today, a cornerstone of
modern anticancer treatment. Better, more discriminating
treatments are urgently needed [83]. With the discovery
of the first oncogenes, starting with the chicken retrovirus
gene sarc, more than 40 years ago, it was rapidly identified
that the normal counterparts of oncogenes would be tran-
scription factors whose proper function was the con-
trol of physiological cell growth. Their modulation would
in turn profoundly affect the course of growth-related
diseases such as cancer [84]. The number of transcription
factors listed as targets of choice for cancer therapy, able
to modulate tumor growth and/or metastasis, has steadily
increased in the last decade (Figure 3). Most promising
research projects are targeting amongst others BRCA1,
a tumor suppressor protein involved in DNA repair;
MYC/MAX heterodimerization, involved in cell prolif-
eration and differentiation suppression; FOXM1, a tran-
scriptional repressor involved in chromosomal segregation
and genomic stability (most intensively investigated with
tumor suppressor p53); as well as FOXA1, a transcription
factor controlling the expression of other genes involved
mostly in hormone-dependent breast cancer [16,43,85].
Other indications Pharmacological manipulation of
transcription factor protein-protein interaction is still in
its infancy. Transcription factors are first and foremost
seen as oncogene counterparts, controlling cancer-related
cell growth disorders. A handful of potential non-cancer
indications have been proposed, however, with prom-
ising results, for example with STAT protein modula-
tors. STAT proteins are a family of transcription factors
shuttling between the cytosol and the nucleus, depend-
ing on their JAK kinase-dependent phosphorylation
status, linked to cytokine membrane receptors. In 2005,
inhibition of STAT3 dimerization was already predicted as
an alternative choice to targeting upstream phosphokinases[10]. This has now become a reality, with psoriasis identi-
fied as a potential indication for modulators of STAT3
dimerization (Figure 3) [88]. A few other indications have
also been identified for protein-protein interaction modula-
tors, like anti-angiogenesis for p300-HIF-1α [89] as well as
type II diabetes for CREB (cAMP response element-binding
protein)-CBP (CREB-binding protein) interaction [90].
Marketed drugs with documented off-target effects
towards TFs
To our knowledge, there is no compiled list of marketed
drugs with documented off-target effects towards transcrip-
tion factors, except for nonsteroidal anti-inflammatory
drugs (NSAIDs) [91]. It has been known for over a decade
that the antineoplastic properties of some NSAIDs are due
to both COX-related and COX-independent modes of ac-
tion. COX-independent antineoplastic modes of action
include modulation of two transcription factors: acti-
vation by direct binding of antineoplastic nuclear receptor
PPARγ and inhibition of transcription factor NFκB-
dependent gene expression [92,93]. A body of evidence is
developing that identifies a possible link between the
two modes of actions via “receptor-interacting-protein-
of-140-kDa” (RIP140), a co-repressor of PPARγ as well as
a co-activator of NFκB-mediated inflammatory gene ex-
pression. Targeting RIP140-protein interactions occurring
along these pathways may open new therapeutic avenues
for not only indications with an inflammatory component,
such as cancer, but also Alzheimer’s disease, type II dia-
betes, and chronic liver or kidney diseases [94-96].
The depletion of physiologically important prostaglandins
due to cyclooxygenase inhibition precludes the long-term
use of antineoplastic NSAIDs for cancer chemopreven-
tion. Conversely, no side effect due to alteration of PPARγ
and NFκB-dependent gene expression has been docu-
mented thus far, arguing for the safety of pharmacological
manipulation of TFs, either via classic approaches or via
PPIDs.
Methodological obstacles to screening and design
of TF modulators
TF recombinant expression and purification
Affinity tag-based protein purification methods differ
largely in terms of purity, yield, capacity, and cost, and
transcription factors are no exception to this rule [97].
However, eukaryotic transcription factors are also re-
nowned for being difficult to express and purify. Because
of the importance of post-translational modifications [98],
TFs should always be expressed in eukaryotic systems,
e.g., CHO, HEK mammalian cells, or insect cells. If yield is
poor in native conditions (low to sub-milligrams per liter),
it should be compared to yield in denaturing conditions,
using lysis, washing, and elution buffers supplemented



























































Figure 3 Transcription factor protein-protein interaction disruptors: heavier, more hydrophobic, and more rigid than regular drugs.
Anticancer indications: a/ BRD4/histone interaction disruptor: BRD4 binds to acetylated lysine residues in histone tails, which act as activation
markers for gene expression. (+)-JQ1 was modeled to fit a hydrophobic cavity in the BRD4 domain that accommodates acetylated lysines.
Potential indications are squamous cancer and acute myeloid leukemia [86]. b/ HDM2(MDM2)/p53 interaction disruptors: Human or mouse
double minute 2 protein binds to tumor suppressor p53, increasing its degradation. Tetra-substituted imidazole, Nutlin-3, disrupts complexes
with nanomolar affinity [87]. Subsequent attempts at computational optimization based on existing PPI descriptors and X-ray crystallography
have generated compounds with low/sub-micromolar affinities PB11 and BDM_4605 [60,72]. Potential indications are all p53-related cancers. c/ Bcl-2
(Bcl-xL)/Bax(Bak) interaction disruptors: Bcl-2 or Bcl-xL binds to the BH3 (Bcl2-homology 3) domain of pro-apoptotic Bax and Bak proteins, preventing
apoptosis. BH3-mimetic ABT-737 disrupts complexes with sub-micromolar affinity, inducing apoptosis. Potential indications are small-cell lung
carcinoma and lymphoma [73]. Other indications: d/ STAT3 is a latent cytoplasmic transcription factor transducing signals from the cell
membrane to the nucleus. STAT3 can dimerize via reciprocal interaction of its Src homology 2 domain (SH2), upon phosphorylation of a
conserved tyrosine within the SH2 domain. STA-21 inhibits cytokine-dependent nuclear translocation of Stat3 in normal human keratinocytes
in vitro by impeding STAT3 DNA binding and dimerization with mid-micromolar potency [88].
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affinity tag in the protein native conformation. According
to the authors’ own experience, however, it is rarely the
case for TFs, which seem to have a rather ill-definednative conformation, even for very small tags. Instead,
solubility issues and co-precipitation with genomic DNA
are the two most common problems encountered. Single-
step glutathione-S-transferase (GST) purification from a
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both issues, providing the best ratio of native to denatur-
ing purification yields and the best cost compromise.
Several fusion proteins have been shown to increase
protein solubility, including 26-kDa GST, the maltose-
binding protein, and the Z-domain from protein A
[99-101]. Two-step affinity purifications, on the other
hand, are often marred with problems of elution buffer in-
compatibility, e.g., the immobilized metal ion affinity chro-
matography (IMAC) elution buffer is not optimal for GST
binding or vice versa. Likewise, addition of a secretion sig-
nal like honeybee “melittin” has been attempted in several
occasions but did not yield any particular improvement to
the method [102].
Finally, for purified transcription factors with severe
stability issues, storage at 4°C on GSH beads may preserve
them from aggregating for a few weeks. With a cleavage
site included either for the human rhinovirus 3C protease
or the cysteine protease of the tobacco etch virus [103],
the GST tag can be easily removed for functional as-
says (pull-down, affinity purification-mass spectrometry)
or crystallization.
Access to suitable annotated small compounds libraries
Screening libraries of synthetic molecules has been pro-
ductive against traditional drug targets, such as ligand-
gated ion channels, kinases, and G protein-coupled
receptors [104,105]. More success may be recorded in
the forthcoming years for enzymes and receptor ligands
identified using metabolomics profiling, i.e., profiling of
small molecules occurring naturally in an organism [3].
Conversely, for antimicrobial targets and targets identified
from genomic studies (including DNA recombination, se-
quencing, and bioinformatics studies), screening product-
ivity has been problematic and is expected to remain so if
some paradigms are not challenged [3]. Because total
chemical space is estimated to be greater than 1060 mole-
cules for a molecular weight below 430 g/Mol−1 (or
Dalton), chemical libraries have to be dramatically biased
towards biological targets to reduce size and improve odds
of random hits. This bias is mainly obtained by mimicking
“biogenic” natural products [106]. Combinatorial chemis-
try has been an essential part of drug discovery for the last
30 years, based on the assumption that increasing the size
and diversity of libraries by systematic combination of
basic chemical motifs bound by Lipinski’s rule of five was
the best approach. For more than a decade now, compari-
sons of combinatorial chemistry libraries with approved
drugs and natural products have repeatedly pointed out a
severe lack of chirality as well as structural rigidity of com-
bichem libraries, the latter widely regarded as a prerequis-
ite for tight binding of small molecules to protein-protein
interfaces [107,108]. This explains at least in part why,
today, only a small number of low-molecular-weight inhibitorsof protein-protein interactions is available [109]. In the
last 5 years, however, new rational drug design methods
have emerged, allowing cost-effective assembly of chem-
ical libraries biased towards protein-protein interaction
inhibitors (Figure 3). New strategies employing machine
learning based on known inhibitors, multicomponent re-
action chemistry (also called “one-pot synthesis”) able to
generate structural complexity in a single step, and associ-
ated with more classical fragment-based drug discovery
approaches will soon generate readily accessible diversity
libraries [59,60,72,110]. However, whether these libraries
will generate higher hit rates for protein-protein inter-
action inhibitors remains to be seen.
Access to high-throughput mapping of protein-protein
interactions
Until recently, protein-protein interaction assays were
amongst the most difficult biochemical assays to deploy
in a molecular biology laboratory, requiring expensive
equipment, expert skills, and time. Affinity purification-
mass spectrometry (AP-MS) and yeast two-hybrid screen-
ing were the only two platforms available until the advent,
5 years ago, of cheaper technologies based on either fluor-
escence (fluorescence anisotropy, Förster resonance en-
ergy transfer, homogenous time-resolved fluorescence,
AlphaScreen, and single-molecule fluorescence), prox-
imity association of fragments into a functional reporter
(a fluorophore or an enzyme), or label-free assays (surface
plasmon resonance, isothermal titration calorimetry)
[111-113]. The most common limitation is the possible
interference of tags used in fluorescence-based or frag-
ment proximity-based assays with protein folding or abil-
ity to interact with partner proteins.
In some instances, protein intra-cellular movements or
translocations observed during signal transduction have
been considered an acceptable surrogate to screen for in-
hibitors of protein-protein interaction, which is playing a
key role in cell signaling [114,115]. This cannot be applied
to intra-cellular protein-protein interactions of transcrip-
tion factors, except if transcriptional activity is regulated
by trafficking partner proteins to and from the cytoplasm,
as is the case for SOX proteins for instance [116].
Conclusion
The number of protein-protein interactions that com-
prise the human interactome is estimated at 650,000
PPIs [117]. Only a minute fraction of these are known
and only a handful of low-molecular-weight disruptors
(PPIDs) have been identified, displaying activities in the
low-to-mid-micromolar concentration range. Protein-
protein interactions are likely to represent one of the next
major classes of therapeutic targets, with PPIDs showing
great potential for further optimization, both in terms of
potency and specificity.
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fluorescent-based assays to genomic-wide RIME, as well
as recent advances in TF proteomics profiling and dy-
namic intra-nuclear visualization methods, can now be
deployed cost-effectively in non-specialist laboratories
(developmental biology, regenerative medicine, micro-
biology, etc.). The timely convergence of all these afford-
able methodologies, amenable to fairly small sample size
such as tissue biopsies, MACS sorted cells (magnetic ac-
tivated cell sorting), and cultured cells, combined with
advances in genome editing technology, will accelerate
the identification of novel targets and the development
of new compounds.
High-resolution NMR and X-ray crystallography of pro-
tein complexes can now be used as templates for the virtual
screening of chemical databases, to identify the so-called
“hot spot” binders. However, translation of structural
knowledge (protein complexes, natural products, or pepti-
domimetic inspirational scaffolds) into rational drug design
still remains a difficult task. Recently, new methodologies
based on machine learning, in silico pharmacophore-based
and in silico anchor-biased screenings, as well as stereo-
selective and one-pot chemical synthesis have led to rap-
idly increasing hit rates.
The era of small-molecule inhibitors of protein-protein
interactions has only just began, and this is even more so
the case for transcription factors.
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